Pharmore GmbH
Drug Brokers · Ibbenbüren
Pharmore GmbH is a drug broker based in Ibbenbüren, Germany.
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Pharmore GmbH Address & Contact
Pharmore GmbH Overview
Pharmore GmbH is a pharmaceutical intermediary based in Ibbenbüren, Lower Saxony (District of Steinfurt, NRW). The company facilitates pharmaceuticals in the German and European market and supports pharmaceutical companies and wholesalers in optimizing their supply chains. As a reliable partner, Pharmore offers solutions that ensure both efficiency and quality for all participants in the pharmaceutical supply chain.
Services and Products
Pharmore intermediates pharmaceutical products and provides extensive consulting services for the pharmaceutical trade. As a pharmaceutical intermediary registered under § 52b AMG, the company operates in compliance with GDP, which means it adheres to the highest standards throughout the entire supply chain. It is particularly noteworthy that Pharmore does not operate its own storage for the intermediated pharmaceuticals, allowing it to respond flexibly to the changing demands of the market.
The product areas covered by Pharmore include both prescription and over-the-counter medications. The offering includes innovative therapies and classical treatment approaches in oncology, cardiology, neurology, and many others. The selection of products is always oriented towards the needs of the customers to ensure an optimal supply basis.
- Pharmaceutical Intermediation: targeted mediation between manufacturers and wholesalers.
- Consulting: comprehensive support in the area of regulatory affairs and market access.
- Supply Chain Optimization: analysis and improvement of existing processes.
- Market Access in Europe: advice and support for distribution across borders.
Regulatory Classification
Pharmore is registered as a pharmaceutical intermediary under § 52b of the Medicines Act (AMG), which provides the company with the legal basis for its activities. This registration guarantees that Pharmore meets all relevant legal requirements, including compliance with Good Distribution Practice (GDP). The focus on quality standards ensures that the intermediated products are both safe and effective.
An important aspect of the regulatory classification is the careful review of the partner companies with which Pharmore collaborates. The company always conducts thorough due diligence in its selection to ensure compliance with all legal regulations and quality requirements.
Regional Importance
Ibbenbüren is located in the district of Steinfurt in the northern Münsterland, a region that has strategic significance in western Germany due to its industrial culture and geographical location. The proximity to large cities such as Münster and Osnabrück enables Pharmore to reach potential partners and customers both regionally and nationally. Several pharmaceutical companies and research institutions are located in this region, making it an attractive center for pharmaceutical services.
Unique Features of Pharmore
A standout feature of Pharmore is the combination of extensive market knowledge and individualized customer care. The company understands the specific needs of its partners and offers tailored solutions to meet diverse requirements. Additionally, Pharmore continually invests in the training of its employees to stay up to date with developments in the pharmaceutical sector.
The close collaboration with international partners and the ability to manage complex supply chains have given Pharmore a central role in pharmaceutical distribution in the European market. This position is strengthened by regular networking activities and participation in industry-specific trade fairs and conferences, allowing Pharmore to remain in constant contact with other players in the industry.
Other pharmaceutical intermediaries: Overview of Pharmaceutical Intermediaries | Pharmaceutical Wholesale | Pharmaceutical Companies
Frequently asked questions about Pharmore GmbH
What does Pharmore GmbH do?
Pharmore ist ein Arzneimittelimporteur in Ibbenbüren, spezialisiert auf Einzelimporte nach § 73 AMG. Das Unternehmen beschafft Arzneimittel aus dem Ausland für Lieferengpässe, neue Therapien und eingestellte Präparate.
Was sind Einzelimporte nach § 73 AMG?
Einzelimporte nach § 73 AMG ermöglichen die Einfuhr von Arzneimitteln aus dem Ausland, die in Deutschland nicht zugelassen oder nicht verfügbar sind. Sie werden auf ärztliche Verschreibung für einzelne Patienten beschafft.
Wie schnell kann Pharmore Arzneimittel liefern?
Pharmore betreibt ein Notfallmanagement mit der Möglichkeit zur Lieferung innerhalb einer Stunde. Das Unternehmen handelt nach dem Motto 'Schnell - zuverlässig - global'.
Drug Brokers in Germany
Related areas in healthcare
Drug Brokers by location
About Drug Brokers
A medicine broker (Arzneimittelvermittler) is a business that arranges the purchase or sale of human medicines between manufacturers, wholesalers and buyers, acting as an intermediary without ever taking physical possession of or legal title to the products. This role is formally defined under Section 4(22b) of the AMG (German Medicinal Products Act). Medicine brokers play a role in international parallel trade and in secondary supply chains, but their activities are subject to strict legal requirements to prevent counterfeit medicines from entering the legitimate supply chain. In Germany, anyone wishing to act as a medicine broker must register with the competent authority of the relevant German federal state under Section 52b AMG. Registration requires a permanent business address in Germany or another EU member state, a designated responsible person, and a fully documented quality management system that meets the requirements of the EU Good Distribution Practice (GDP) guidelines for medicine brokers. Failure to register or to maintain the required quality system constitutes a criminal offence under German pharmaceutical law. The registration system ensures traceability and accountability throughout the supply chain. Medicine brokers must not procure medicines from unlicensed sources or supply non-authorised products. The GDP requirements specific to brokers include record keeping, complaint handling, recall procedures and counterfeiting detection. This directory lists all medicine brokers registered with German authorities under Section 52b AMG, with addresses and contact details.
Medicine Brokering in Germany: Legal Framework
Medicine brokering is a regulated activity in Germany and across the European Union, governed by the EU Falsified Medicines Directive (2011/62/EU) and its implementing measures, transposed into German law through amendments to the AMG. The formal definition of a medicine broker (Arzneimittelvermittler) is set out in Section 4(22b) AMG: a natural or legal person who arranges transactions involving medicinal products for human use between manufacturers, wholesalers and buyers, without themselves acquiring or supplying the products and without taking physical possession of them. This intermediary role distinguishes brokers from wholesalers. The registration requirement under Section 52b AMG was introduced specifically to increase transparency and traceability in the medicine supply chain, after investigations revealed that unlicensed brokers had been involved in the entry of substandard or falsified medicines into European supply chains. Germany's registration system requires brokers to notify the competent state authority before commencing operations and to maintain their registration as long as they are active.
GDP Quality System Requirements for Medicine Brokers
Although medicine brokers do not physically handle medicines, they are still required to operate a documented quality management system (QMS) under the EU GDP guidelines for brokers (2013/C 343/01, Part III). The QMS must cover several key areas: written procedures (SOPs) for all brokering activities, a system for verifying that all counterpart manufacturers and wholesalers hold the required licences, a complaints handling system for quality-related issues, a product recall procedure that can be activated even though the broker did not physically move the goods, record keeping for a minimum of five years for all brokered transactions, and procedures for detecting and reporting suspected falsified medicines to the competent authority. Brokers must not source from or supply to unlicensed parties. Regular self-inspections and, where relevant, external audits ensure the QMS remains effective. The competent state authority may inspect a broker's QMS as part of its oversight activities.
Medicine Brokering and Parallel Trade in the EU
Medicine brokering is closely associated with parallel trade (Parallelhandel) in the EU pharmaceutical market. Parallel trade occurs when an authorised medicine is purchased in an EU member state where its price is lower and resold in another member state where the price is higher, exploiting price differentials across the single market. Germany, as a large market with relatively higher medicine prices than some southern and eastern European member states, is a significant destination for parallel-traded medicines. Parallel importers must obtain a parallel import permit from BfArM or PEI for each product, ensuring the imported medicine is equivalent to the authorised German version. Medicine brokers can play a role in arranging these cross-border transactions. However, all parties in the parallel trade supply chain, including brokers, must comply with applicable GDP and registration requirements. The Falsified Medicines Directive's safety features (tamper-evident packaging and unique identifiers under the EU Falsified Medicines Verification System, EMVS) apply to all prescription medicines circulating in Germany.
Compliance and GDP Requirements for Brokers
Pharmaceutical brokers remain under strict regulatory oversight despite not handling products physically. A broker's GDP quality system must include procedures for order processing, supplier qualification, complaints management, recall management and self-inspections. All brokered medicinal products must originate from legal, officially approved sources; transaction documentation must be kept comprehensively and retained for at least five years. Suspected falsified medicines must be reported to the competent authority. The European Commission defined clear requirements for brokers without product ownership in GDP Guidelines 2013/C 343/01. Regular self-inspections and the designation of a Responsible Person (RP) are mandatory. Violations can result in deregistration and criminal consequences under the Medicines Act. The Sanoliste directory only lists brokers who were registered in accordance with Section 52b AMG at the time of their entry.
What does a medicine broker do?
A medicine broker, as defined under Section 4(22b) of the AMG (German Medicinal Products Act), arranges transactions in human medicines without taking ownership of the products or physically handling them. Brokers must be registered with the responsible authority and maintain a quality management system.
What registration does a medicine broker need?
Medicine brokers must register under Section 52b AMG with the responsible state authority. Requirements include an official business address in Germany and a documented quality system meeting GDP (Good Distribution Practice) standards.
Where can I find registered medicine brokers in Germany?
The competent state pharmaceutical supervisory authority in each federal state maintains a register of brokers registered under Section 52b AMG. Sanoliste provides a searchable overview of registered medicine brokers across Germany with contact details and addresses.
Why are medicine brokers regulated in Germany?
Regulation of medicine brokers in Germany is primarily aimed at preventing counterfeit and substandard medicines from entering the legitimate pharmaceutical supply chain. By requiring registration and a documented GDP quality system, authorities can trace the origin and movement of medicines arranged by brokers. This protects patients and ensures that only authorised medicines from authorised sources reach pharmacies and hospitals.
What are the GDP requirements for medicine brokers in Germany?
Under EU GDP guidelines (2013/C 343/01), medicine brokers must maintain a quality system that covers written procedures, complaint handling, product recall procedures, record keeping and measures to detect falsified medicines. They must only deal with manufacturers and wholesalers that hold the appropriate authorisations. These requirements apply equally to brokers registered in Germany under Section 52b AMG.
How does medicine brokering differ from pharmaceutical wholesale in Germany?
The key difference is physical possession. A pharmaceutical wholesaler (Pharmagrosshandel) physically stores and ships medicinal products and requires a wholesale dealer authorisation under Section 52a AMG. A medicine broker (Arzneimittelvermittler) never takes possession of the goods; it only acts as an intermediary arranging deals between other parties. Brokers require registration under Section 52b AMG rather than a full wholesale authorisation.